Facilitated By

San Antonio Medical Foundation

A DUAL PHASE 1/2 INVESTIGATOR INITIATED STUDY TO DETERMINE THE MAXIMUM TOLERATED DOSE, SAFETY, AND EFFICACY OF RHENIUM NANOLIPOSOMES (RNL) IN RECURRENT GLIOBLASTOMA (CTRC #12-02)

UT Health San Antonio

The UT Health San Antonio, with missions of teaching, research and healing, is one of the country’s leading health sciences universities.

Principal Investigator(s)
Brenner,Andrew
Funded by
NANOTX THERAPEUTICS
Research Start Date
Status
Inactive
Clinical Care
Drug Discovery
Cancer